Topical ocular preparation of botulinum toxin for use in ocular surface disease
View Patent ↗A composition of botulinum toxin is claimed which can penetrate into the ocular surface inclusive of a penetration through a conjunctiva, cornea, and other structures. This composition allows for a maximal penetration of a topical preparation of botulinum toxin which serves to reduce the need for frequent allergy drops for the treatment of ocular surface disease and other conditions causing ocular surface inflammation or deep ocular inflammation. No puncture of the needle is necessary for the administration. Herein describes a novel composition using several principles based on composition, method of application, which enhances the effectiveness of the penetration.
1. A topical formulation comprising:
a botulinum toxin;
a topical anesthetic; and
a protein bulking agent.
2. The formulation of claim 1 , wherein the topical anesthetic is selected from the group consisting of cocaine, bupivacaine, proparacaine, tetracaine, lidocaine, Xylocaine, novocaine, and piperocaine.
3. The formulation of claim 1 , wherein the topical formulation is applied with the placement of a contact lens.
4. The formulation of claim 3 , wherein the contact lens is a scleral contact lens.
5. The formulation of claim 1 , wherein the topical formulation is a cohesive ointment.
6. The formulation of claim 1 , wherein the formulation is a solution.
7. A topical formulation comprising:
a botulinum toxin; and
a topical anesthetic,
wherein the formulation is hypertonic relative to the human corneal tissue and tear film.
8. A topical formulation comprising:
a botulinum toxin; and
a topical anesthetic,
wherein the formulation is hypotonic relative to the human corneal tissue and tear film.
9. The formulation of claim 1 , wherein botulinum toxin is type A.
10. The formulation of claim 9 , wherein the botulinum toxin is selected from the types consisting of A sub-type 1, A sub-type 2, A sub-type 3, A sub-type 4, or A sub-type 5.
11. The formulation of claim 1 , wherein the botulinum toxin is quantitated at 2.5 to 250 units per mL.
12. The formulation of claim 1 , wherein the botulinum toxin is quantitated from 300 to 400 units per mL.
13. The formulation of claim 1 wherein the formulation is used to treat ocular surface inflammation arising from herpes simplex or herpes zoster.
14. The formulation of claim 1 in which the formulation is used to treat ocular surface inflammation related to dry eye syndrome, intolerance to glaucoma medication, or acne rosacea.
15. A method of treating allergic conjunctivitis comprising:
selecting a patient having allergic conjunctivitis;
applying a pharmaceutically effective amount of the formulation of claim 1 to the patient;
thereby treating the allergic conjunctivitis.
16. The method of claim 15 , wherein each application of the formulation effectively treats the allergic conjunctivitis for at least one month.
17. The formulation of claim 7 , wherein the topical anesthetic is selected from the group consisting of cocaine, bupivacaine, proparacaine, tetracaine, lidocaine, Xylocaine, novocaine, and piperocaine.
18. The formulation of claim 7 , wherein the topical formulation is a cohesive ointment.
19. The formulation of claim 7 , wherein the formulation is a solution.
20. The formulation of claim 7 , wherein botulinum toxin is type A.
21. The formulation of claim 7 , wherein the botulinum toxin is quantitated at 2.5 to 250 units per mL.
22. The formulation of claim 8 , wherein the topical anesthetic is selected from the group consisting of cocaine, bupivacaine, proparacaine, tetracaine, lidocaine, Xylocaine, novocaine, and piperocaine.
23. The formulation of claim 8 , wherein the topical formulation is a cohesive ointment.
24. The formulation of claim 8 , wherein the formulation is a solution.
25. The formulation of claim 8 , wherein botulinum toxin is type A.
26. The formulation of claim 8 , wherein the botulinum toxin is quantitated at 2.5 to 250 units per mL.
27. A topical formulation comprising:
a botulinum toxin;
a topical anesthetic, wherein the topical anesthetic is tetracaine.
28. The formulation of claim 27 , wherein the topical formulation is a cohesive ointment.
29. The formulation of claim 27 , wherein the formulation is a solution.
30. The formulation of claim 27 , wherein botulinum toxin is type A.
31. The formulation of claim 27 , wherein the botulinum toxin is quantitated at 2.5 to 250 units per mL.